Adenoviral Vector Encoding HPV Antigens for Cross-Reactive Immunity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for persistent cervical HPV infections and low-grade HPV lesions are inadequate, leading to stress and anxiety due to the risk of progression to cervical cancer, as there is a lack of effective therapeutic options.
Innovation Solution
Development of nucleic acid constructs encoding antigenic peptides from HPV early proteins, specifically adenoviral vectors that induce cross-reactive cell-mediated immunity against multiple high-risk HPV types, using recombinant vectors like ChAd155 to administer these constructs and elicit an immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If adenoviral vectors encoding multiple HPV early protein antigens are administered, then cross-reactive cell-mediated immunity against multiple high-risk HPV types is induced, but the complexity of the immunogenic composition increases
Solution Approach 1:
The patent combines multiple nucleic acid constructs encoding different HPV early protein antigens (E6, E7) from multiple high-risk HPV types into a single adenoviral vector system. This merging approach allows simultaneous delivery of multiple antigens to induce cross-reactive immunity against HPV types 16, 18, 31, 33, 45, 52, and 58, resolving the contradiction by integrating multiple functions into one compositional unit.
Solution Approach 2:
The adenoviral vector is designed with multi-functionality to encode and express multiple different HPV antigens from various high-risk types. This universal design enables a single immunogenic composition to provide broad-spectrum protection against multiple HPV types, achieving versatility without requiring separate vaccines for each HPV type.
2Reliability
If nucleic acid constructs encoding HPV early proteins are used to induce cell-mediated immunity, then therapeutic effect against persistent infection is achieved, but the manufacturing precision requirements increase
Solution Approach 1:
The adenoviral vector serves as an intermediary carrier that simplifies the delivery of multiple HPV antigen-encoding nucleic acid constructs. Instead of directly administering complex nucleic acid assemblies, the viral vector mediates transport and expression, ensuring reliable therapeutic effect while reducing manufacturing precision requirements through standardized viral production protocols.
Solution Approach 2:
The nucleic acid constructs within the adenoviral vector are designed to self-express the HPV antigens upon delivery to host cells. The constructs contain necessary regulatory elements for transcription and translation, allowing them to autonomously produce the therapeutic antigens without requiring complex external manufacturing or delivery mechanisms, thereby reducing precision requirements.
Data Source
AI summary
The present invention relates to nucleic acid constructs capable of encoding antigenic peptides or polypeptides derived from multiple Human Papilloma Virus (HPV) early proteins, and to immunogenic compositions comprising such nucleic acid constructs and a pharmaceutically acceptable carrier. Such nucleic acid constructs and immunogenic compositions are useful in the treatment of persistent HPV infection and low-grade HPV lesions, particularly infections and lesions of human anogenital epithelial tissue, such as cervical epithelia.